| Dedication |
|
v | |
| Contributors |
|
vii | |
| Preface |
|
xix | |
|
PART 1 Serotonin in the CNS |
|
|
|
Chapter 1 Multiple facets of serotonergic modulation |
|
|
3 | (38) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4 | (1) |
|
2 Cellular organization of 5-HT receptors beyond auto/hetero receptor discrimination |
|
|
5 | (5) |
|
2.1 Region-specific expression of different 5-HTRs |
|
|
5 | (3) |
|
2.2 Cell type-specific expression of different 5-HTRs |
|
|
8 | (1) |
|
2.3 Co-expression of different 5-HTRs in a single cell |
|
|
9 | (1) |
|
3 Regulations of the 5-HT tone by 5-HT |
|
|
10 | (13) |
|
3.1 Serotonin autoregulation |
|
|
11 | (7) |
|
3.2 The short loops involved in the regulation of 5-HT neuron activity |
|
|
18 | (4) |
|
3.3 The long loops altering the activity of DRN/MRN neurons |
|
|
22 | (1) |
|
|
|
23 | (1) |
|
|
|
24 | (17) |
|
Chapter 2 Anatomical and neurochemical organization of the serotonergic system in the mammalian brain and in particular the involvement of the dorsal raphe nucleus in relation to neurological diseases |
|
|
41 | (42) |
|
|
|
|
|
|
|
|
|
42 | (1) |
|
|
|
42 | (11) |
|
|
|
43 | (1) |
|
2.2 Efferent projections of the DRN |
|
|
44 | (1) |
|
|
|
45 | (1) |
|
2.4 Overview of DRN connectivity |
|
|
45 | (6) |
|
2.5 DRN input and output connections |
|
|
51 | (2) |
|
3 Neurotransmitters of the rat DRN |
|
|
53 | (7) |
|
|
|
53 | (2) |
|
|
|
55 | (3) |
|
3.3 Interaction between DA and 5-HT |
|
|
58 | (2) |
|
4 Functional neuroanatomy of the DRN with emphasis on depression |
|
|
60 | (8) |
|
4.1 Serotonergic system and its interaction with cytokines in depressive disease |
|
|
61 | (1) |
|
4.2 Serotonergic system in depressive disease |
|
|
61 | (1) |
|
|
|
62 | (1) |
|
|
|
63 | (2) |
|
4.5 Interaction between cytokines and serotonergic system |
|
|
65 | (1) |
|
4.6 Cytokines and 5-HT receptors and transporters |
|
|
66 | (1) |
|
4.7 Molecular organization of the DRN |
|
|
66 | (1) |
|
4.8 Ubiquitin proteasome system, DRN and AD |
|
|
67 | (1) |
|
|
|
68 | (1) |
|
|
|
69 | (1) |
|
|
|
70 | (13) |
|
Chapter 3 Serotonin modulation of hippocampal functions: From anatomy to neurotherapeutics |
|
|
83 | (78) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
85 | (1) |
|
|
|
85 | (3) |
|
|
|
85 | (1) |
|
2.2 Hippocampal cell types |
|
|
86 | (2) |
|
3 Serotonergic system in the hippocampus |
|
|
88 | (12) |
|
3.1 Projection to the hippocampal region |
|
|
88 | (1) |
|
|
|
89 | (11) |
|
4 The regulation of neurotransmitter tones by 5-HT in the hippocampus |
|
|
100 | (6) |
|
4.1 Regulation of 5-HT neurotransmission by 5-HT mechanisms |
|
|
100 | (2) |
|
4.2 Regulation of cholinergic neurotransmission by 5-HT mechanisms |
|
|
102 | (2) |
|
4.3 Regulation of glutamatergic neurotransmission by 5-HT mechanisms |
|
|
104 | (1) |
|
4.4 Regulation of catecholaminergic neurotransmission by 5-HT mechanisms |
|
|
105 | (1) |
|
4.5 Regulation of neurotransmission by 5-HT mechanisms: Conclusion |
|
|
106 | (1) |
|
5 Functional aspects of 5-HT controls on hippocampal function: From cell responses to behavior |
|
|
106 | (9) |
|
|
|
106 | (9) |
|
6 Hippocampal 5-HT system dysregulation in brain diseases |
|
|
115 | (12) |
|
6.1 Overview of the hippocampal 5-HT system in brain diseases |
|
|
115 | (1) |
|
|
|
116 | (3) |
|
6.3 Mesial temporal lobe epilepsy |
|
|
119 | (3) |
|
|
|
122 | (4) |
|
|
|
126 | (1) |
|
|
|
127 | (1) |
|
|
|
128 | (1) |
|
|
|
129 | (32) |
|
PART 2 Serotonin-dopamine interactions |
|
|
|
Chapter 4 Serotonin/dopamine interaction: Electrophysiological and neurochemical evidence |
|
|
161 | (104) |
|
|
|
|
|
|
|
|
|
163 | (1) |
|
2 Neuroanatomical basis of the 5-HT/DA systems interaction |
|
|
164 | (4) |
|
|
|
165 | (2) |
|
|
|
167 | (1) |
|
2.3 Function and distribution of 5-HT receptors in DA areas |
|
|
167 | (1) |
|
3 Global changes of 5-HT function upon DA neurotransmission |
|
|
168 | (8) |
|
3.1 Reduction of central 5-HT transmission on basal DA neurotransmission |
|
|
169 | (1) |
|
3.2 Activation of central/local 5-HT transmission on basal DA neurotransmission |
|
|
170 | (6) |
|
4 5-HT1A receptor and the control of DA neurotransmission |
|
|
176 | (7) |
|
4.1 Distribution of 5-HT1A receptors |
|
|
176 | (1) |
|
4.2 Control exerted by 5-HT1A receptors on basal DA neurotransmission |
|
|
176 | (2) |
|
4.3 Control exerted by 5-HT1A receptors on activated DA neurotransmission |
|
|
178 | (1) |
|
4.4 5-HT1A receptors and DA function in neuropsychiatric diseases |
|
|
178 | (5) |
|
5 5-HTib receptor and the control of DA neurotransmission |
|
|
183 | (1) |
|
5.1 Distribution of 5-HTiB receptors |
|
|
183 | (1) |
|
5.2 Control exerted by 5-HT1B receptors on basal DA neurotransmission |
|
|
183 | (1) |
|
5.3 Control exerted by 5-HT1B receptors on activated DA neurotransmission |
|
|
184 | (1) |
|
5.4 5-HT1B receptors and DA function in neuropsychiatric diseases |
|
|
184 | (1) |
|
6 5-HT2A receptor and the control of DA neurotransmission |
|
|
184 | (10) |
|
6.1 Distribution of 5-ht2a receptors |
|
|
184 | (1) |
|
6.2 Control exerted by 5-HT2A receptors on basal DA neurotransmission |
|
|
185 | (3) |
|
6.3 Control exerted by 5-HT2A receptors on activated DA neurotransmission |
|
|
188 | (4) |
|
6.4 5-HT2A receptors on DA function in neuropsychiatric diseases |
|
|
192 | (2) |
|
7 5-HT2B receptor and the control of DA neurotransmission |
|
|
194 | (4) |
|
7.1 Distribution of 5-HT2B receptors |
|
|
194 | (1) |
|
7.2 Control exerted by 5-HT2B receptors on resting and activated DA neurotransmission |
|
|
195 | (2) |
|
7.3 5-HT2B receptors as a target in neuropsychiatric diseases with DA dimension |
|
|
197 | (1) |
|
8 5-HT2C receptor and the control of DA neurotransmission |
|
|
198 | (9) |
|
8.1 Distribution of 5-HT2C receptors |
|
|
198 | (2) |
|
8.2 Control exerted by 5-HT2c receptors on resting DA neurotransmission |
|
|
200 | (4) |
|
8.3 Control exerted by 5-HT2C receptors on activated DA neurotransmission |
|
|
204 | (1) |
|
8.4 5-HT2C receptors and DA function in neuropsychiatric diseases |
|
|
205 | (2) |
|
9 Control exerted by 5-HT3 receptors in therapies |
|
|
207 | (5) |
|
9.1 Distribution of 5-HT3 receptors |
|
|
207 | (1) |
|
9.2 Control exerted by 5-HT3 receptors on resting DA neurotransmission |
|
|
208 | (1) |
|
9.3 Control exerted by 5-HT3 receptors on activated DA neurotransmission |
|
|
209 | (1) |
|
9.4 5-HT3 receptors and DA function in neuropsychiatric diseases |
|
|
210 | (2) |
|
10 Controls exerted by 5-HT4 receptors on DA neurons |
|
|
212 | (3) |
|
10.1 Distribution of 5-HT4 receptors |
|
|
212 | (1) |
|
10.2 Control exerted by 5-HT4 receptors on resting DA neurotransmission |
|
|
212 | (1) |
|
10.3 Control exerted by 5-HT4 receptors on activated DA neurotransmission |
|
|
213 | (1) |
|
10.4 5-HT4 receptors and DA function in neuropsychiatric diseases |
|
|
213 | (2) |
|
11 Controls exerted by 5-HT6 receptors on DA Neurons |
|
|
215 | (3) |
|
11.1 Distribution of 5-HT6 receptors |
|
|
215 | (1) |
|
11.2 Controls exerted by 5-HT6 receptors on resting DA neuron function |
|
|
216 | (1) |
|
11.3 Controls exerted by 5-HT6 receptors on activated DA neuron function |
|
|
217 | (1) |
|
11.4 5-HT6 receptors and DA neuron function in neuropsychiatric diseases |
|
|
217 | (1) |
|
|
|
218 | (1) |
|
|
|
218 | (47) |
|
Chapter 5 Breathing new life into neurotoxic-based monkey models of Parkinson's disease to study the complex biological interplay between serotonin and dopamine |
|
|
265 | (22) |
|
|
|
1 Parkinson's disease and serotonin |
|
|
266 | (1) |
|
2 Importance of the MPTP neurotoxin in modeling Parkinson's disease in monkeys |
|
|
267 | (4) |
|
3 MDMA as a tool for implementing the MPTP monkey model |
|
|
271 | (1) |
|
4 Impact of MDMA administration on MPTP-intoxicated monkeys |
|
|
272 | (2) |
|
5 Impact of prior MDMA administration |
|
|
274 | (1) |
|
|
|
275 | (1) |
|
|
|
276 | (11) |
|
Chapter 6 Serotonin/dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesia: An update |
|
|
287 | (16) |
|
|
|
|
|
|
|
|
|
297 | (1) |
|
|
|
297 | (6) |
|
Chapter 7 Serotonergic imaging in Parkinson's disease |
|
|
303 | (38) |
|
Edoardo Rosario de Natale |
|
|
|
|
|
|
|
|
304 | (1) |
|
2 Biology of serotonin in Parkinson's disease |
|
|
305 | (2) |
|
3 In vivo molecular study of the serotonergic system in PD |
|
|
307 | (1) |
|
4 Molecular imaging of the serotonergic system |
|
|
307 | (3) |
|
5 Use of molecular imaging for the study of the serotonergic system in PD |
|
|
310 | (11) |
|
|
|
312 | (1) |
|
|
|
312 | (1) |
|
5.3 Pathophysiology of levodopa induced dyskinesia and graft induced dyskinesia |
|
|
313 | (2) |
|
|
|
315 | (6) |
|
6 Pathophysiology of serotonin modulation in Parkinson's disease |
|
|
321 | (1) |
|
7 Imaging of the serotonergic system in monogenic forms of Parkinson's |
|
|
322 | (1) |
|
|
|
323 | (1) |
|
|
|
324 | (17) |
|
PART 3 Serotonin-Glutamate interaction |
|
|
|
Chapter 8 Cortical influences of serotonin and glutamate on layer pyramidal neurons |
|
|
341 | (38) |
|
|
|
|
|
1 Serotonergic modulation of the mPFC/neocortex |
|
|
342 | (1) |
|
2 Thalamocortical loops as important determinants of mPFC/neocortical function |
|
|
342 | (1) |
|
3 Postsynaptic effects of serotonin on mPFC/neocortical layer pyramidal cells |
|
|
343 | (1) |
|
4 Presynaptic 5-HT2a receptor activation induces glutamate release onto layer pyramidal neuron dendrites |
|
|
343 | (4) |
|
5 Presynaptic modulation of 5-HT-induced EPSPs/EPSCs by metabotropic glutamate receptors |
|
|
347 | (3) |
|
6 Midline/Intralaminar thalamic nuclei is a source of afferents for 5-HT-induced EPSCs/EPSPs |
|
|
350 | (5) |
|
7 5-HT2A receptor activation and immediate early gene-like responses in mPFC/neocortex |
|
|
355 | (3) |
|
8 Head twitches as a behavior manifestation of mPFC function |
|
|
358 | (2) |
|
9 Motoric impulsivity and DRL 72-s behavior reflecting mPFC function |
|
|
360 | (3) |
|
10 5-ht2a-mGlu2 heterocomplex |
|
|
363 | (1) |
|
11 Recent clinical Implications of 5-HT2A receptor inverse agonists and mGlu2 receptor PAMs: Major Depressive Disorder (MDD) |
|
|
364 | (2) |
|
12 Recent clinical implications of serotonergic hallucinogens and MDD |
|
|
366 | (1) |
|
|
|
367 | (1) |
|
|
|
368 | (11) |
|
Chapter 9 Alterations and interactions of subcortical modulatory systems in Alzheimer's disease |
|
|
379 | (44) |
|
|
|
|
|
|
|
|
|
381 | (1) |
|
2 Alterations in subcortical systems in Alzheimer's disease |
|
|
382 | (14) |
|
|
|
382 | (4) |
|
|
|
386 | (3) |
|
|
|
389 | (2) |
|
|
|
391 | (3) |
|
|
|
394 | (2) |
|
3 Interactions of the serotonergic and other subcortical systems in Alzheimer's disease |
|
|
396 | (5) |
|
|
|
396 | (1) |
|
|
|
397 | (1) |
|
|
|
398 | (1) |
|
|
|
399 | (2) |
|
|
|
401 | (1) |
|
|
|
401 | (1) |
|
|
|
401 | (1) |
|
|
|
402 | (21) |
|
Chapter 10 Serotonergic control of the glutamatergic neurons of the subthalamic nucleus |
|
|
423 | |
|
|
|
|
|
|
|
424 | (1) |
|
2 The STN in the basal ganglia |
|
|
425 | (4) |
|
2.1 The STN, a glutamatergic structure |
|
|
425 | (1) |
|
2.2 The functional role of the STN in the basal ganglia |
|
|
426 | (3) |
|
3 The 5-HT system and the STN |
|
|
429 | (2) |
|
3.1 The 5-HT system at a glance |
|
|
429 | (1) |
|
3.2 Anatomy of the 5-HT system in the STN |
|
|
430 | (1) |
|
4 Electrophysiological evidence for 5-HT control of STN neuronal activity |
|
|
431 | (3) |
|
4.1 5-HT system and drugs altering 5-HT levels |
|
|
431 | (1) |
|
4.2 The influence of 5-HT receptor subtypes |
|
|
432 | (2) |
|
|
|
434 | (1) |
|
5 Neurochemical and cell imaging data of the STN |
|
|
434 | (4) |
|
5.1 Effect of the 5-HT system on markers of activity in the STN |
|
|
434 | (2) |
|
5.2 5-HT drugs/conditions and neurochemical markers |
|
|
436 | (1) |
|
5.3 STN impact on 5-HT neuronal activity |
|
|
436 | (1) |
|
5.4 Behavioral studies reporting STN control of 5-HT behaviors |
|
|
437 | (1) |
|
6 5-HT and STN functions in Parkinson's disease |
|
|
438 | (6) |
|
6.1 5-HT function in Parkinson's disease |
|
|
438 | (1) |
|
6.2 STN function in Parkinson's disease |
|
|
439 | (1) |
|
6.3 The 5-HT control of the STN in Parkinson's disease |
|
|
439 | (2) |
|
6.4 The 5-HT system and the STN in L-DOPA-induced motor benefit and dyskinesia in Parkinson's disease |
|
|
441 | (3) |
|
6.5 5-HT and STN function in side effects related to mood in Parkinson's disease treatment |
|
|
444 | (1) |
|
7 5-HT and STN function in decision making |
|
|
444 | (1) |
|
|
|
445 | (1) |
|
|
|
446 | (1) |
|
|
|
446 | |
Lisainfo e-raamatute kohta